Nasdaq

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any ...

SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE: AGN), a ...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety ...
Medscape

Levonorgestrel-Releasing Intrauterine System May Reduce Menstrual Blood Loss

August 26, 2010 — For women with documented idiopathic heavy menstrual bleeding, the levonorgestrel-releasing intrauterine system is associated with a greater reduction in menstrual blood loss and a ...
Insurancenewsnet.com

Estimated Economic Impact of the Levonorgestrel Intrauterine System on Unintended Pregnancy in Active Duty Women

Nearly half of all pregnancies in the United States are unin- tended,1 which is defined as any pregnancy either mistimed, unplanned, or unwanted.2,3 Prior studies on unintended preg- nancy in the ...
Medscape

Levonorgestrel System Eases Effects of Menorrhagia

A levonorgestrel-releasing intrauterine system was more effective than usual medical treatments in alleviating the adverse effects of menorrhagia on women's lives, a 2-year primary care–based study ...
PharmiWeb

Levosert® (52mg levonorgestrel intrauterine system [IUS]) receives an 8-year licence extension in the UK for contraception

· Levosert is effective for 8 years in the contraception indication and has demonstrated efficacy for 3 years in the indication of heavy menstrual bleeding. 1 Therefore, Levosert should be removed or ...
News Medical

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA™ ...
Business Insider

FDA Approves Medicines360's Supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg as Treatment of Heavy Menstrual Bleeding

New Indication Expected to Increase Treatment Options of Heavy Menstrual Bleeding for up to five years in patients who choose intrauterine contraception as their method of contraception SAN FRANCISCO, ...
MedPage Today

Levonorgestrel IUD Safe, Effective for 5 Years of Contraceptive Use

Levonorgestrel intrauterine system is safe and efficacious for contraception over a 5-year period, data from a phase III trial found. Pearl Indices, or the number of unintentional pregnancies, for ...
Pharmabiz

Bayer initiates phase III study SUNFLOWER with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia

Bayer initiates phase III study SUNFLOWER with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia: Berlin Wednesday, December 3, 2025, ...
EurekAlert!

Breast cancer in users of levonorgestrel-releasing intrauterine systems

About The Study: This Danish nationwide study found an association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and increased breast cancer risk in females ages 15 to 49, ...